Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Income from Continuing Operations (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Income from Continuing Operations for 2 consecutive years, with 18120000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 49.06% to 18120000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 79867000.0 through Dec 2025, down 0.57% year-over-year, with the annual reading at 79635000.0 for FY2025, 2.98% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 18120000.0 at Pyxis Oncology, up from 22003000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 5343000.0 in Q1 2024, with the low at 35571000.0 in Q4 2024.